Names
Rezurock™ BelumosudilIndications and usage
Rezurock™ is approved for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
Side effects needing medical attention
The most common adverse reactions, including laboratory abnormalities, were infections, decreased muscle strength (asthenia), nausea, diarrhea, difficult or labored breathing (dyspnea), cough, edema, hemorrhage, abdominal pain, musculoskeletal pain, headache, phosphate decreased, gamma glutamyl transferase increased, lymphocytes decreased, and hypertension.